Immunovant shares hit 52-week high of $41.37
Immunovant’s stock surged to a fresh 52-week peak, extending gains amid biotech sector momentum.
Immunovant Inc. shares reached a 52-week high of $41.37 on Thursday, marking the company’s strongest valuation in the past year.
The biopharmaceutical firm’s stock performance reflects broader investor optimism in the biotech sector, where companies developing treatments for autoimmune diseases have seen increased attention. Immunovant’s rise follows recent clinical updates and analyst upgrades that have bolstered confidence in its pipeline.
The 52-week high was recorded in after-hours trading, with the stock briefly touching $41.37 before paring gains. Trading volumes were elevated compared to the 30-day average, indicating heightened market interest.
The company, which focuses on developing therapies for autoimmune disorders, has not commented publicly on the price movement. Its market capitalization now stands near $5.2 billion, up from $4.8 billion at the start of the month.
Immunovant’s stock has gained approximately 18% over the past three months, outpacing the broader biotech index, which is up 12% in the same period.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →